Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 926544
                    [Title] => Experts highlight vildagliptin’s novel mechanism of action
                    [Summary] => 
With their novel mechanism of action, DPP-4 inhibitors such as vildagliptin are an excellent addition to currently available oral treatments for type 2 diabetes.

                    [DatePublished] => 2013-04-04 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 719781
                    [Title] => Drug significantly cuts  hypoglycemic events
                    [Summary] => 
A newly published study showed that the Novartis oral diabetes medication vildagliptin, when taken with metformin, caused no hypoglycemia, was well adhered to and improved blood sugar levels in South Asian patients with type 2 diabetes mellitus (T2DM) fasting during daylight hours for Ramadan.
                    [DatePublished] => 2011-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 560595
                    [Title] => New diabetes treatment option for Pinoy patients
                    [Summary] => 
An estimated three million people in the country have type 2 diabetes. Controlling blood sugar levels is difficult even among patients receiving treatment and only less than 30 percent of Filipino patients are meeting their recommended blood sugar goals.
                    [DatePublished] => 2010-03-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

vildagliptin

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 926544
                    [Title] => Experts highlight vildagliptin’s novel mechanism of action
                    [Summary] => 
With their novel mechanism of action, DPP-4 inhibitors such as vildagliptin are an excellent addition to currently available oral treatments for type 2 diabetes.

                    [DatePublished] => 2013-04-04 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 719781
                    [Title] => Drug significantly cuts  hypoglycemic events
                    [Summary] => 
A newly published study showed that the Novartis oral diabetes medication vildagliptin, when taken with metformin, caused no hypoglycemia, was well adhered to and improved blood sugar levels in South Asian patients with type 2 diabetes mellitus (T2DM) fasting during daylight hours for Ramadan.
                    [DatePublished] => 2011-08-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 560595
                    [Title] => New diabetes treatment option for Pinoy patients
                    [Summary] => 
An estimated three million people in the country have type 2 diabetes. Controlling blood sugar levels is difficult even among patients receiving treatment and only less than 30 percent of Filipino patients are meeting their recommended blood sugar goals.
                    [DatePublished] => 2010-03-25 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Experts highlight vildagliptin’s novel mechanism of action

April 4, 2013 - 12:00am

With their novel mechanism of action, DPP-4 inhibitors such as vildagliptin are an excellent addition to currently available oral treatments for type 2 diabetes.

Science and Environment

Drug significantly cuts hypoglycemic events

August 25, 2011 - 12:00am

A newly published study showed that the Novartis oral diabetes medication vildagliptin, when taken with metformin, caused no hypoglycemia, was well adhered to and improved blood sugar levels in South Asian patients...

Science and Environment

New diabetes treatment option for Pinoy patients

March 25, 2010 - 12:00am

An estimated three million people in the country have type 2 diabetes. Controlling blood sugar levels is difficult even among patients receiving treatment and only less than 30 percent of Filipino patients are meeting...

Science and Environment